MEDIFAST (MED)
(Delayed Data from NYSE)
$19.53 USD
+0.69 (3.66%)
Updated Jul 25, 2024 03:52 PM ET
After-Market: $19.53 0.00 (0.00%) 7:18 PM ET
5-Strong Sell of 5 5
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
MED 19.53 +0.69(3.66%)
Will MED be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MED
Medifast (MED) Lags Industry in 3 Months: How to Play Ahead?
Medifast (MED) Tumbles More Than 40% in 3 Months: Here's Why
MED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medifast (MED) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
Medifast's (MED) Transformation on Track Amid Macro Headwinds
MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
Other News for MED
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2024
Time to Unload: 3 Stocks in Deep Trouble to Sell Now
70 All Star And Graham Value Stocks: 56 Fit To Buy In July
D.A. Davidson Sticks to Its Sell Rating for Medifast (MED)
7 Consumer Staples Stocks to Buy at a 52-Week Low in July